Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 2,317 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Multiple Myeloma Clear all
Completed Phase 1Phase 2 Interventional Results available

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

NCT00448357
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
rabbit anti-thymocyte globulin (ATG), therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, methotrexate
Biological · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 25, 2026, 5:06 PM EDT
Recruiting Phase 2 Interventional

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

NCT05145400
View directory record Official record
Conditions
Multiple Myeloma, Cancer
Interventions
Isatuximab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
5
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 25, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

NCT05347485
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cilta-cel, Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
18
States / cities
Duarte, California • San Francisco, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 25, 2026, 5:06 PM EDT
Completed Phase 1 Interventional Results available

CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

NCT01995708
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs), Standard of care
Biological · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 25, 2026, 5:06 PM EDT
Active, not recruiting Phase 1 Interventional

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

NCT06042725
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Computed Tomography, Daratumumab, Dexamethasone, Lenalidomide, Low Dose Computed Tomography of the Whole Body, Magnetic Resonance Imaging, Positron Emission Tomography, Venetoclax, X-Ray Imaging, Questionnaire Administration
Procedure · Biological · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 25, 2026, 5:06 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

NCT07075185
View directory record Official record
Conditions
Multiple Myeloma in Relapse, Myeloma Multiple, Multiple Myeloma Progression, Neoplasms by Histologic Type, Neoplasm, Hemostatic Disorders, Vascular Disorder, Paraproteinemias, Blood Protein Disorders, Hematologic Disease and Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Disease, Gene Therapy
Interventions
KLN-1010
Drug
Lead sponsor
Kelonia Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2042
U.S. locations
8
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 25, 2026, 5:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

NCT01057225
View directory record Official record
Conditions
Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
carfilzomib, cyclophosphamide, thalidomide, dexamethasone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
3
States / cities
Scottsdale, Arizona • Rochester, Minnesota • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 25, 2026, 5:06 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

NCT06271252
View directory record Official record
Conditions
Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorders, Vascular Diseases, Cardiovascular Diseases, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Diseases, Multiple Myeloma
Interventions
OriCAR-017
Drug
Lead sponsor
OriCell Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 25, 2026, 5:06 PM EDT
Terminated Phase 2 Interventional

Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

NCT03590652
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Ixazomib, Pomalidomide, Dexamethasone, Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 25, 2026, 5:06 PM EDT
Recruiting Phase 1Phase 2 Interventional

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

NCT06785415
View directory record Official record
Conditions
Recurrent Multiple Myeloma
Interventions
Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Chest Radiography, Computed Tomography, Daratumumab, Dexamethasone, Elotuzumab, Iberdomide, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 25, 2026, 5:06 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

NCT04504825
View directory record Official record
Conditions
AL Amyloidosis
Interventions
CAEL-101, Placebo, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
26
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 25, 2026, 5:06 PM EDT
Completed Phase 1Phase 2 Interventional

Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

NCT00004158
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
melphalan, peripheral blood stem cell transplantation, holmium Ho 166 DOTMP
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
4
States / cities
Miami, Florida • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Oct 25, 2026, 5:06 PM EDT
Terminated Phase 1 Interventional Results available

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

NCT02716805
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Tremelimumab, Durvalumab, Prevnar-13, Melphalan
Drug · Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 25, 2026, 5:06 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence

NCT02681302
View directory record Official record
Conditions
Multiple Myeloma, Lymphoma
Interventions
Ipilimumab, Nivolumab
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 25, 2026, 5:06 PM EDT
Terminated Phase 2 Interventional Results available

Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant

NCT01078441
View directory record Official record
Conditions
Refractory Multiple Myeloma
Interventions
liposomal doxorubicin, bortezomib, dexamethasone, cyclophosphamide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
130
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 94 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Oct 25, 2026, 5:06 PM EDT
Completed Not applicable Interventional

In Person and Mobile Health Coping Skills Training for Improving Symptom Management and Daily Steps in Hematopoietic Stem Cell Transplant Patients

NCT03960619
View directory record Official record
Conditions
Hematopoietic Neoplasms (Leukemia, Lymphoma, Multiple Myeloma)
Interventions
coping skills training
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 25, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

NCT00514137
View directory record Official record
Conditions
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
sunitinib malate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 25, 2026, 5:06 PM EDT
Completed Phase 1 Interventional

Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF

NCT00952237
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Other Plasma Cell Dyscrasia (Waldenstrom, Amyloidosis), Leukemia
Interventions
GM-CSF, IL-2
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 25, 2026, 5:06 PM EDT
Completed Phase 3 Interventional Results available

UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma

NCT01621672
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Revlimid
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 25, 2026, 5:06 PM EDT
Completed Not applicable Interventional

Muscle Stimulation for Physical Function During Stem Cell Transplant

NCT04364256
View directory record Official record
Conditions
Autologous Hematopoietic Stem Cell Transplant
Interventions
RS-4i Plus Sequential Stimulator (RS Medical, Vancouver, WA)
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 25, 2026, 5:06 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

NCT01564537
View directory record Official record
Conditions
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Ixazomib, Lenalidomide, Dexamethasone, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
18
States / cities
Little Rock, Arkansas • Anaheim, California • Berkeley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 25, 2026, 5:06 PM EDT
Completed Phase 1 Interventional

NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

NCT04136756
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma
Interventions
NKTR-255, NKTR-255 Q21, Rituximab, Daratumumab
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
13
States / cities
Goodyear, Arizona • Duarte, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 25, 2026, 5:06 PM EDT
Not listed Phase 1Phase 2 Interventional Results available

Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma

NCT02004275
View directory record Official record
Conditions
Multiple Myeloma in Relapse
Interventions
pomalidomide, ixazomib, dexamethasone
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
336
States / cities
Anchorage, Alaska • Burbank, California • La Jolla, California + 237 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 25, 2026, 5:06 PM EDT
Terminated Phase 1 Interventional

Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies

NCT00473551
View directory record Official record
Conditions
Leukemia, Lymphoma, Myeloma
Interventions
Rituximab, Cyclophosphamide, Fludarabine, Mesna, Radiation Treatment, Stem Cell Transplantation (SCT), Sirolimus, Anti-third Party Cytolytic T-lymphocytes (CTL)
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2011 · Synced Oct 25, 2026, 5:06 PM EDT